Newsletter Tool

Today's Rundown

Featured Story

Slaoui will return $3.86M to GlaxoSmithKline after his dismissal for sexual harassment

By Kevin Dunleavy

Former Operation Warp Speed chief Moncef Slaoui, who GlaxoSmithKline fired last year because of a sexual harassment claim, is returning $3.86 million to the company, according to its annual executive compensation report.

Senate narrowly votes to get rid of COVID-19 national emergency

By Robert King

The Senate narrowly passed a resolution calling for an end to the COVID-19 national emergency, which garnered a White House veto threat.

Eli Lilly extends winning streak as it keeps the TV ad spend throne holding off Regeneron's Dupixent

By Ben Adams

It’s as things were in January for the first two spots of pharma’s top TV ad spenders. In February again, Lilly’s diabetes drug Trulicity came in at No. 1 with a hefty $45.8 million spend, while Regeneron and Sanofi’s Dupixent sat in second.

Shionogi's COVID-19 vaccine matches Pfizer's Comirnaty in booster trial

By Nick Paul Taylor

Shionogi’s COVID-19 vaccine candidate has held its own against Pfizer’s Comirnaty in a study of the effect of booster shots on antibody levels, offering the company encouragement as it barrels toward a filing for approval of S-268019 in Japan.

Fitbit recalls nearly 1M Ionic smartwatches in US due to burn hazard

By Heather Landi

Fitbit is voluntarily recalling about 1.7 million Ionic smartwatches sold globally because the product's lithium-ion battery can overheat, posing a burn hazard.

vTv CEO resigns 4 months into job after slashing workforce, refocusing pipeline

By Kyle LaHucik

Deepa Prasad has resigned as CEO and president of vTv Therapeutics just four months into the job after having prioritized the biotech's pipeline to focus on Type 1 diabetes and having laid off 65% of the company in December.

3 in 4 infusion pumps vulnerable to cyberattacks: study

By Conor Hale

Palo Alto Networks used scans of more than 200,000 smart infusion pumps and discovered that 75% had at least one known and publicly documented security gaps.

Evolus' has something to smile about as neurotoxin Jeuveau's 2021 sales swell 76%

By Fraiser Kansteiner

Evolus’ Jeuveau garnered $34.7 million in the fourth quarter and $99.7 million in full-year 2021 sales, rising more than 76% over the $56.6 million it made in 2020. Evolus credited those gains to boosted sales volume and the med’s higher price point in the U.S. The company also highlighted the success of its beauty-first, millennial-targeted marketing push.

BeiGene's hematology CMO resigns in wake of solid tumor switch

By Nick Paul Taylor

BeiGene’s hematology chief medical officer is hitting the exit. Almost six years after joining BeiGene, Jane Huang has handed in her resignation shortly after the replacement of her solid tumor counterpart.

Allscripts sells hospital business unit in $700M deal with Constellation subsidiary

By Rebecca Torrence

Health IT company Allscripts will sell its hospital and large physician practices business segment to a subsidiary of Constellation Software in a deal worth up to $700 million that's expected to close in the second quarter of 2022.

Fierce Pharma Asia—J&J, Legend's CAR-T nod; Biocon's $3.3B Viatris biosimilar buy; Sanofi-Adagene tie-up

By Angus Liu

Legend Biotech and Janssen's CAR-T therapy Carvykti has won an FDA go-ahead to challenge Bristol Myers Squibb in multiple myeloma. Biocon Biologics is buying partner Viatris' biosimilars business. Sanofi taps Adagene's "safe" antibody technology in a deal potentially worth $2.5 billion. And more.

Dry AMD treatment developer LumiThera nets retinal diagnostic maker Diopsys